United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, June 8th. The shares were sold at an average price of $547.49, for a total value of $5,201,155.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $22,180,462.37. The trade was a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
United Therapeutics Stock Up 1.6%
United Therapeutics stock traded up $8.45 during mid-day trading on Tuesday, hitting $553.14. 325,572 shares of the company’s stock traded hands, compared to its average volume of 479,193. The firm has a 50 day moving average price of $568.47 and a 200 day moving average price of $519.64. The company has a market cap of $23.48 billion, a PE ratio of 20.42, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period in the previous year, the firm earned $6.63 EPS. The firm’s revenue was down 1.6% on a year-over-year basis. On average, analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.
Analyst Ratings Changes
View Our Latest Report on UTHR
Institutional Investors Weigh In On United Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of UTHR. Wellington Management Group LLP raised its position in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics during the third quarter worth $317,617,000. Norges Bank acquired a new stake in shares of United Therapeutics during the fourth quarter worth $293,418,000. Avoro Capital Advisors LLC raised its position in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC raised its position in shares of United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
- Five stocks we like better than United Therapeutics
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
